Skip to main content
Premium Trial:

Request an Annual Quote

Oncgnostics Epigenetic Cervical Cancer Test Wins Chinese Regulatory Approval

NEW YORK – German firm Oncgnostics said on Thursday that China's National Medical Products Administration approved its DNA methylation-based cervical cancer GynTect assay.

Shanghai-based biotech GeneoDx, a subsidiary of the Sinopharm Group, will distribute the test there under an exclusive license.

The GynTect assay detects cancer-related changes in DNA methylation from cervical smears. It is designed to provide confirmation or identify a predisposition for cervical cancer in patients with abnormal findings, such as a positive HPV test, from a cervical cancer screen.

The Chinese approval follows a multiyear study of approximately 10,000 participants, which Oncgnostics said demonstrated a high sensitivity and specificity.

"Our China partners have done a remarkable job with their elaborate study," Alfred Hansel, Oncgnostics' managing director, said in a statement. "The subsequent approval for the Chinese market is an important milestone for both our partner and our company."

Financial details of the licensing and distribution agreement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.